Concepedia

Amir Harandi

AH

Statistics

Publications

5

Citations

180

H-Index

5

Active since

2006

Affiliations

Florida Cancer Specialists & Research Institute(Current)

University of California San Diego

Merus (Netherlands)

Sarah Cannon Research Institute

Université Claude Bernard Lyon 1

Amir Harandi is an author at Florida Cancer Specialists & Research Institute specializing in cancer immunotherapy, medicine, and oncology.

Publications per year

2006–2025

5

Publications

5

Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers

Amir Harandi, Aisha Zaidi, Abigail Stocker et al. · Journal of Oncology · 2009 · 114 citations · Full text

Medicine, Oncology, Pharmacology +16

1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C

M.D. Galsky, Vadim S. Koshkin, Matthew T. Campbell et al. · Annals of Oncology · 2024 · 25 citations

Medicine, Oncology, Pharmacology +16

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.

Jérôme Fayette, Florian Clatot, Irene Braña et al. · Journal of Clinical Oncology · 2024 · 18 citations

Medicine, Oncology, Pharmacology +15

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial.

Carla M.L. van Herpen, Amaury Daste, Virginia Arrazubi et al. · Journal of Clinical Oncology · 2025 · 12 citations

Medicine, Oncology, Pharmacology +17

Induction of antitumor immunity through xenoplacental immunization

Zhaohui Zhong, Kornel P. Kusznieruk, Igor A. Popov et al. · Journal of Translational Medicine · 2006 · 11 citations · Full text

Medicine, Immunology, Oncology +17

1–5 of 5